The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) reached all time high today, Nov, 22 and still has $122.33 target or 3.00% above today’s $118.77 share price. This indicates more upside for the $10.74B company. This technical setup was reported by Barchart.com. If the $122.33 PT is reached, the company will be worth $322.20 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 399,561 shares traded hands. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 46.36% since April 20, 2016 and is uptrending. It has outperformed by 41.81% the S&P500.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Ratings Coverage
Out of 7 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 3 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 43% are positive. IDEXX Laboratories has been the topic of 13 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The rating was maintained by Stifel Nicolaus on Thursday, October 29 with “Buy”. On Thursday, August 13 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Neutral” rating given on Friday, April 1 by CL King. The company was reinitiated on Thursday, September 29 by Bank of America. On Thursday, July 23 the stock rating was maintained by Canaccord Genuity with “Buy”. Credit Suisse initiated IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Thursday, February 4 with “Outperform” rating. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Market Perform” rating by Raymond James on Friday, August 28. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Buy” rating given on Monday, March 21 by Stifel Nicolaus. Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) rating on Wednesday, July 20. Canaccord Genuity has “Buy” rating and $98 price target. The firm earned “Hold” rating on Friday, July 24 by Feltl & Co.
According to Zacks Investment Research, “IDEXX Laboratories, Inc. is a world leader in providing diagnostic, detection, and information products to the animal health industry as well as quality assurance products and services to the food and water industries.”
Insitutional Activity: The institutional sentiment decreased to 1.14 in Q2 2016. Its down 0.20, from 1.34 in 2016Q1. The ratio fall, as 27 funds sold all IDEXX Laboratories, Inc. shares owned while 123 reduced positions. 79 funds bought stakes while 122 increased positions. They now own 77.90 million shares or 5.94% less from 82.81 million shares in 2016Q1.
Firstmerit Bancorporation N A Trustee has 0.02% invested in the company for 2,537 shares. The Maryland-based Carderock Management has invested 2.86% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Schroder Inv Mngmt Group Inc Inc accumulated 0% or 5,420 shares. Schaper Benz & Wise Investment Counsel Inc Wi holds 55,575 shares or 0.93% of its portfolio. The Kentucky-based Harvey Commerce Limited Liability has invested 2.8% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Ls Investment Advsr Limited Liability Company holds 8,625 shares or 0.06% of its portfolio. Franklin Resource holds 0.02% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 411,483 shares. Raymond James Trust Na holds 0.03% or 4,322 shares in its portfolio. Biondo Investment Llc last reported 2.74% of its portfolio in the stock. Geneva Advsr Limited Liability Com has 0.94% invested in the company for 513,360 shares. Quantitative Investment Mngmt Lc has 20,600 shares for 0.09% of their US portfolio. Renaissance Limited Liability Corporation holds 0.09% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 537,404 shares. Goldman Sachs Grp has 784,722 shares for 0.02% of their US portfolio. The United Kingdom-based Ahl Prtn Limited Liability Partnership has invested 0.14% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Moreover, Schwab Charles Inv Mngmt Incorporated has 0.03% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 255,951 shares.
Insider Transactions: Since August 4, 2016, the stock had 0 insider purchases, and 7 selling transactions for $19.47 million net activity. AYERS JONATHAN W also sold $4.31M worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Wednesday, November 9. On Thursday, August 25 the insider HENDERSON REBECCA M sold $1.10M. Another trade for 9,924 shares valued at $1.11M was made by JOHNSON BARRY C on Monday, August 15. Williams Michael J PhD had sold 49,560 shares worth $5.40 million on Monday, August 8. END WILLIAM T sold 5,000 shares worth $549,359.
More notable recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Prnewswire.com which released: “IDEXX Laboratories Announces Departure of Executive Vice President Michael …” on November 15, 2016, also Fool.com with their article: “Why IDEXX Laboratories, Inc. Reported Higher Today” published on August 02, 2016, Fool.com published: “IDEXX Laboratories, Inc. Sees More Growth Ahead” on May 02, 2016. More interesting news about IDEXX Laboratories, Inc. (NASDAQ:IDXX) were released by: Prnewswire.com and their article: “IDEXX Laboratories to Host 2016 Investor Day” published on August 08, 2016 as well as Prnewswire.com‘s news article titled: “IDEXX Welcomes Healthcare Technology Veteran Pat Venters as Chief Marketing …” with publication date: November 14, 2016.
IDXX Company Profile
IDEXX Laboratories, Inc., incorporated in 1983, develops, makes and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Firm operates through three divisions: diagnostic and information technology services and products for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller divisions that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.